Add To...

    RTIX  Rti Biologics Inc.

    Exchange

    NASDAQ

    Sector

    Health Care

    Industry

    Industrial Specialties

    Market Cap.

    242.5M

    Vuru Grade

    40.14/100

    Current Price

    $4.33
    -0.05 (-1.14%)

    Growth Price

    $5.29
    Undervalued by 22.28%

    Stability Price

    $-1.20
    Why is this negative?

    Company Overview

    Management
    Financial Strength
    Economic Moat
    Dividends & Buybacks

    Company Metrics

    • 31.29 P/E
    • 1.4 P/S
    • 1.32 P/B
    • 0.14 EPS
    • 5.64% Cash ROIC
    • 1.30 Cash Ratio
    • 0 / 0% Dividend
    • 290,940.00 Avg. Vol.
    • 56.00M Shares
    • 242.5M Market Cap.

    Company Description

    RTI Biologics, Inc. and its subsidiaries produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues, and improve surgical outcomes. The company processes human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium, and sclera and dermal tissues into allografts, as well as bovine...
    more


    Download 10 Years of Financial Statements:
    Income Statement   Balance Sheet   Cash Flow

    News

    RTI Biologics, Inc. (RTIX) Tops Q1 EPS by 1c; Boosts FY13 Outlook
    StreetInsider.com (subscription) - Apr 25, 2013
    RTI Biologics, Inc. sees FY2013 EPS of $0.17-0.19, versus the consensus of $0.17. RTI Biologics, Inc. sees FY2013 revenue of $179-182 million, versus prior guidance of $178-179 million and the consensus of $178.3 million.
    RTI BIOLOGICS INC. : RTI Biologics Announces 2013 First Quarter Results
    4-traders (press release) - Apr 25, 2013
    RTI's innovations continuously raise the bar of science and safety for biologics - from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization ...
    RTI Biologics Q1 13 Earnings Conference Call At 8:30 AM ET - NASDAQ.com
    NASDAQ - Apr 25, 2013
    (RTTNews.com) - RTI Biologics Inc.( RTIX ) will host a conference call at 8:30 AM ETApril 25, 2013, to discuss its Q1 13 earnings results.
    RTI Biologics Price Target Lowered to $5.00 at Canaccord Genuity (RTIX)
    The Utah People's Post - Apr 30, 2013
    RTI Biologics logo RTI Biologics (NASDAQ: RTIX) had its price target lowered by Canaccord Genuity from $5.50 to $5.00 in a research report released on Friday morning, Stock Ratings Network reports.
    US/Canada daily earnings hits & misses April 25 - 1500 ET
    Reuters - Apr 25, 2013
    ... 1884.3 1911.2 26.9 RR DONNELLEY & SONS COM Q1 COMMUNICATIONS USD 0.33 0.37 0.05 2457.9 2538.5 80.7 RTI BIOLOGICS INC Q1 BIOTECHNOLOGY USD 0.02 0.02 0.00 38.8 40.4 1.7 SAFEGUARD SCIENTIFICS INC Q1 OTHER COMPUTERS ...
    US/Canada daily earnings hits & misses April 25 - 0500 ET - Globe and Mail
    Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
    Seeking Alpha - May 3, 2013
    First and foremost is the partnership with RTI Biologics, Inc. (RTIX) for bone allografts for orthopedic purposes. RTI is using Athersys's patented stem cell technology and Athersys is entitled to $30M from RTI for milestone payments in addition to ...
    DIARY-NON S&P WEEK AHEAD
    Reuters - Apr 25, 2013
    -0.01 3 0.05 25 Apr BMO Q1 2013 RTI Biologics, Inc. 0.02 8 0.04 25 Apr BMO Q1 2013 Rayonier Inc 0.61 8 0.42 25 Apr AMC Q1 2013 Seacoast Banking Corp.
    Musculoskeletal News Roundup 26-Apr-13
    HealthpointCapital - Apr 25, 2013
    RTI Biologics reported financial results for 1Q:13. Total revenue was $40.4 ... SpineFrontier, Inc. announced the launch of its PedFuse REmind Pedicle Screw System, intended for Less Exposure Surgery (LES) Midline Lumbar Surgery.